A Phase 1 Study of Vinorelbine Liposomes Injection (VLI) for Treatment in Patients With Advanced Solid Tumors, Non-Hodgkin's Lymphoma or Hodgkin's Disease
The objectives of this study are:
- To assess the safety and tolerability of treatment with VLI.
- To determine the maximum tolerated dose (MTD) of VLI.
- To characterize the pharmacokinetic (PK) profile of VLI.
- To explore preliminary tumor response of VLI.
Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Evaluate the safety and tolerability of VLI.
John Sarantopoulos, MD
Cancer Therapy and Research Center, Texas
United States: Food and Drug Administration
|Cancer Therapy and Research Center||San Antonio, Texas 78229|
|South Texas Accelerated Research Therapeutics||San Antonio, Texas 78229|